Met in Urological Cancers

Molecular Profiling of Infiltrating Urothelial Carcinoma of Bladder and Nonbladder Origin

(2015) Sherri Z. Millis et al.   Clinical Genitourinary Cancer

A phase I study of cabozantinib (XL184) in patients with renal cell cancer

(2014) T. K. Choueiri et al.   ANNALS OF ONCOLOGY

MicroRNA-34A inhibits the growth, invasion and metastasis of gastric cancer by targeting PDGFR and MET expression

(2014) Yang Peng et al.   BIOSCIENCE REPORTS

A DNA aptamer to c-Met inhibits cancer cell migration

(2014) R. Ueki et al.   CHEMICAL COMMUNICATIONS

c-Met signaling in the development of tumorigenesis and chemoresistance: Potential applications in pancreatic cancer

(2014) Daniel Delitto   WORLD JOURNAL OF GASTROENTEROLOGY

The tumour suppressor miR-34c targets MET in prostate cancer cells

(2013) Z Hagman et al.   BRITISH JOURNAL OF CANCER

Cancer statistics, 2013

(2013) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Prostate cancer stem-like cells/cancer-initiating cells have an autocrine system of hepatocyte growth factor

(2013) Sachiyo Nishida et al.   CANCER SCIENCE

The emerging role of MET/HGF inhibitors in oncology

(2013) Giorgio V. Scagliotti et al.   CANCER TREATMENT REVIEWS

Thrombospondin-1 in Urological Cancer: Pathological Role, Clinical Significance, and Therapeutic Prospects

(2013) Yasuyoshi Miyata et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

From AR to c-Met: Androgen deprivation leads to a signaling pathway switch in prostate cancer cells

(2013) TIANCHENG LIU et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

The Current State of Molecularly Targeted Drugs Targeting HGF/Met

(2013) S. Yano et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Randomized, Placebo-Controlled, Phase III Trial of Sunitinib Plus Prednisone Versus Prednisone Alone in Progressive, Metastatic, Castration-Resistant Prostate Cancer

(2013) M. Dror Michaelson et al.   JOURNAL OF CLINICAL ONCOLOGY

Developing biomarkers to predict benefit from HGF/MET pathway inhibitors

(2013) Hartmut Koeppen et al.   JOURNAL OF PATHOLOGY

c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma

(2012) G. T. Gibney et al.   ANNALS OF ONCOLOGY

Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma

(2012) Toni K. Choueiri et al.   JOURNAL OF CLINICAL ONCOLOGY

Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial

(2012) David C. Smith et al.   JOURNAL OF CLINICAL ONCOLOGY

Abstract A233: Cabozantinib (XL184), a dual MET-VEGFR2 inhibitor, blocks osteoblastic and osteolytic progression of human prostate cancer xenografts in mouse bone.

(2012) F. Schimmoller et al.   MOLECULAR CANCER THERAPEUTICS

A Meta-Analysis of the Relationship between FGFR3 and TP53 Mutations in Bladder Cancer

(2012) Yann Neuzillet et al.   PLoS One

Small molecule tolfenamic acid inhibits PC-3 cell proliferation and invasion in vitro, and tumor growth in orthotopic mouse model for prostate cancer

(2012) Umesh T. Sankpal et al.   PROSTATE

High c-MET expression is frequent but not associated with early PSA recurrence in prostate cancer

(2012) FRANK JACOBSEN et al.   Experimental and Therapeutic Medicine

Transcriptional activation of the Axl and PDGFR-α by c-Met through a ras- and Src-independent mechanism in human bladder cancer

(2011) Chen-Yun Yeh et al.   BMC CANCER

Phase I Trial of a Selective c-MET Inhibitor ARQ 197 Incorporating Proof of Mechanism Pharmacodynamic Studies

(2011) Timothy A. Yap et al.   JOURNAL OF CLINICAL ONCOLOGY

Unknown

(2011) Minja Pfeiffer et al.   MOLECULAR MEDICINE

Activation of c-MET Induces a Stem-Like Phenotype in Human Prostate Cancer

(2011) Geert J. L. H. van Leenders et al.   PLoS One

Effects of transferred NK4 gene on proliferation, migration, invasion and apoptosis of human prostate cancer DU145 cells

(2010) Dan Yue et al.   ASIAN JOURNAL OF ANDROLOGY

Efficacy of c-Met inhibitor for advanced prostate cancer

(2010) William H Tu et al.   BMC CANCER

A Phase I Study of Foretinib, a Multi-Targeted Inhibitor of c-Met and Vascular Endothelial Growth Factor Receptor 2

(2010) J. P. Eder et al.   CLINICAL CANCER RESEARCH

Clinical implications ofMETgene copy number in lung cancer

(2010) Luca Toschi et al.   Future Oncology

MET signalling: principles and functions in development, organ regeneration and cancer

(2010) Livio Trusolino et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Targeting the Met signaling pathway in renal cancer

(2009) Alessio Giubellino et al.   Expert Review of Anticancer Therapy

Phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor growth and prognosis in patients with bladder cancer: correlation with matrix metalloproteinase–2 and –7 and E-cadherin

(2009) Yasuyoshi Miyata et al.   HUMAN PATHOLOGY

Synergistic proapoptotic effects of the two tyrosine kinase inhibitors pazopanib and lapatinib on multiple carcinoma cell lines

(2009) K A Olaussen et al.   ONCOGENE

In vitro propagation and characterization of neoplastic stem/progenitor-like cells from human prostate cancer tissue

(2009) Natalia Guzmán-Ramírez et al.   PROSTATE

A Phase II Clinical Trial of Sorafenib in Androgen-Independent Prostate Cancer

(2008) W. L. Dahut et al.   CLINICAL CANCER RESEARCH

Prognostic Value of MET, RON and Histoprognostic Factors for Urothelial Carcinoma in the Upper Urinary Tract

(2008) E. Compérat et al.   JOURNAL OF UROLOGY

Androgen receptor is a tumor suppressor and proliferator in prostate cancer

(2008) Y. Niu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA